allakos.jpg
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 16:02 ET | Allakos Inc.
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
allakos.jpg
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024 07:02 ET | Allakos Inc.
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers...
allakos.jpg
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024 07:02 ET | Allakos Inc.
–  Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN...
allakos.jpg
Allakos Announces a Restructuring to Focus on Development of AK006
January 16, 2024 07:02 ET | Allakos Inc.
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy...
allakos.jpg
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
January 16, 2024 07:00 ET | Allakos Inc.
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast...
allakos.jpg
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
November 13, 2023 16:02 ET | Allakos Inc.
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
allakos.jpg
Allakos Appoints Neil Graham to its Board of Directors
August 30, 2023 16:05 ET | Allakos Inc.
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
allakos.jpg
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023 16:02 ET | Allakos Inc.
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
allakos.jpg
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
August 02, 2023 16:05 ET | Allakos Inc.
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
allakos.jpg
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
June 12, 2023 07:02 ET | Allakos Inc.
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated...